Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- US Biotech Zogenix Launches Japan Arm, Dravet Syndrome Med Filing Eyed in 2021
June 11, 2021
- Takeda Boasts 10-Plus Immune-Harnessing Compounds in Early Pipeline: Oncology Update
June 10, 2021
- Eisai CEO Says Aducanumab Price Tag Reflects Its Value, 1 Million Patients Estimated in Japan
June 10, 2021
- Kitasato Institute, Meiji Kick Off R&D of Ivermectin Derivatives-Based COVID-19 Meds
June 10, 2021
- Nippon Chemiphar, Sumitomo Dainippon Team Up on Antidepressant R&D
June 10, 2021
- Aducanumab Gets Accelerated OK, Expert Says FDA Verdict Would Affect Japan Review Too
June 9, 2021
- Novo, Chiba University, Asahi City Join Hands to Combat Diabetes
June 9, 2021
- Takeda Chips in for Govt’s Workplace COVID-19 Immunization Drive
June 9, 2021
- Japan Drug Makers Derive Near-60% of FY2020 Sales Overseas as Home Market Falters: Tally
June 8, 2021
- FDA Approves Aducanumab, 1st Disease-Modifying Therapy for Alzheimer’s
June 8, 2021
- Japan Ethical Drug Sales Down 2.4% in April: Crecon
June 8, 2021
- Keytruda Retrieves Top-Selling Crown in Japan in May: Encise
June 8, 2021
- Daiichi Sankyo’s ADC U3-1402 Scores 39% ORR for EGFR-Mutated NSCLC in PI
June 8, 2021
- Bristol Myers, Other Pharma Players Moving to Join Workplace Vaccination Campaign
June 7, 2021
- Kobayashi Kako’s 116-Day Suspension Over, but No Timeline for Resumption
June 7, 2021
- Reps’ Face-to-Face Meetings Up 60% YOY in April, but Fall Shy of Prepandemic Level: Intage
June 7, 2021
- AstraZeneca Launches Exploratory Study to Predict Onset of ILD in NSCLC Patients on Imfinzi
June 7, 2021
- MSD Japan Spins Off Organon Women’s Health Biz, Ryota Sakurai Takes Helm
June 4, 2021
- Aspen Japan to Be Renamed Sandoz Pharma in September
June 4, 2021
- Astellas Plans to Cut 450 Jobs via Voluntary Redundancy Program
June 4, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…